In addition, upregulation of OCT3 expression in colon cancer xenografts via treatment with the DNA methyltransferase inhibitor decitabine increased the cellular concentration of the drug and improved its curative effect[21]. This evidence concerns the gene SLC22A3 and colonic neoplasm.